Liver Metastases
- The liver is downstream of the gut's drainage, so it's the body's most popular landing pad for spreading cancer — metastases are the most common malignant liver tumor overall.
- The classic story is multiple lesions of similar type scattered through both lobes, in someone with a known primary cancer.
- The single most useful trick is timing the contrast: most mets enhance less than the bright liver around them, so they show up best on the portal venous phase as darker holes.
- A few primaries (neuroendocrine, renal, thyroid, melanoma) flip the script and light up brightly in the arterial phase — they're the "hypervascular" exceptions worth memorizing.
- One liver lesion in a cancer patient is not automatically a met; benign things are common, and you sometimes have to prove it.
Think of the liver as the body's customs checkpoint. Almost everything absorbed from your intestines gets funneled through the portal vein straight into the liver before it's allowed anywhere else. That's great for filtering toxins. It's terrible when the thing floating downstream is a clump of tumor cells looking for a place to settle. The liver catches them, gives them a warm blood supply, and — much to everyone's dismay — they move in. That's a liver metastasis: a colony of cancer that started somewhere else and emigrated here.
Why the liver, and why so many
Two things make the liver a metastatic magnet. First, that portal vein plumbing means gut cancers — colon, pancreas, stomach — drain directly into it. Second, the liver has a huge, slow, generous blood supply, which is exactly the kind of neighborhood a wandering tumor cell wants. Put those together and you get the headline fact: across the whole body, metastases are the most common malignant tumor the liver ever grows. The liver's own cancer (hepatocellular carcinoma) gets more textbook glory, but in sheer numbers, mets win.
Because they arrive through the bloodstream and seed randomly, mets are usually multiple and scattered through both lobes, and they tend to look like each other — a litter of similar-looking lesions rather than one lonely oddball. That pattern, in a patient with a known primary cancer, is the whole diagnosis most of the time.
The contrast-timing trick
Here's the single most important idea on the page, so let me belabor it. The liver gets blood from two taps: a small one from the hepatic artery, and a big one from the portal vein. When you inject IV contrast and scan at different times, normal liver lights up brightest a little later — during the portal venous phase — because most of its blood is arriving through that big portal tap.
Most metastases live mainly off the artery and don't share in that portal-phase surge. So during the portal venous phase, the background liver gets bright while the mets stay relatively dark — and they pop out as darker holes in a bright field. We call those hypovascular or hypoenhancing mets, and they're the common ones (colon and pancreas being the usual suspects).
For hunting the common (hypovascular) mets, the portal venous phase is your money shot: bright liver, dark lesions.
The bright exceptions
Not every met plays dark. A handful of primaries grow tumors with a rich arterial supply, so they flare up brightly during the arterial phase, before the rest of the liver catches up — these are the hypervascular mets. The classic list is neuroendocrine tumors, renal cell carcinoma, thyroid cancer, and melanoma. (A friend taught me to remember it as the cancers that are a little too enthusiastic about their blood supply.) These can hide on a portal-venous-only scan because by then they've blended back into the bright liver — which is exactly why we scan multiple phases.
If you only grab one phase, you'll miss the hypervascular mets that flash early and fade. When the primary is neuroendocrine, renal, thyroid, or melanoma, make sure the protocol includes an arterial phase — otherwise a brightly-enhancing met can vanish into the background by the portal phase.
On the other scanners
| Modality | What a met tends to look like |
|---|---|
| Ultrasound | Often a "target" or bullseye — a lesion with a darker rim around a brighter center (or vice versa). Variable, so it screens more than it confirms. |
| CT (with contrast) | Multiple round lesions, usually hypodense to liver on portal venous phase; hypervascular types enhance on arterial phase. |
| MRI | The most sensitive, especially with diffusion-weighted imaging and a liver-specific contrast agent; mets typically restrict diffusion and don't take up the hepatocyte agent, staying dark on delayed images. |
MRI deserves a note: it's the problem-solver. When CT is equivocal or you need to count every last lesion before surgery, MRI's diffusion-weighted sequences make cellular tumor light up, and liver-specific contrast exploits the fact that mets aren't real liver cells — so on the delayed "hepatobiliary" images, normal liver glows and the mets stay dark.
Don't over-call it
A tempting trap: one spot on the liver in a cancer patient must be a met, right? Not so fast. Benign lesions — simple cysts and hemangiomas especially — are extremely common and show up in plenty of people who also happen to have cancer. A tiny lesion too small to characterize is often nothing. Calling something a met has huge consequences for staging and treatment, so the honest read is sometimes "indeterminate, needs MRI or follow-up" rather than a confident verdict.
Liver mets rarely travel alone. Whoever found them was probably staging a known cancer — most often colorectal — so the liver findings get read alongside the lungs, nodes, and the rest of the body. Liver and lung are the two classic distant sites; the same workup that catches one usually catches the other.
The bottom line: when you see multiple similar lesions sprinkled across both lobes in someone with a primary tumor, think mets first — then let the contrast timing tell you whether you're hunting dark holes or bright flares.